Sandra Delistathis, MD
Internal Medicine · Silver Spring, MDNPI 1023009974
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 34.1% of the total. Reporting peaked in 2019 at $132 and has fallen 59.8% since, to $53 in 2025.
Across 16 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$100
- Astellas Pharma US Inc$57
- Daiichi Sankyo Inc.$33
- Novo Nordisk$27
- Neos Therapeutics, LP$22
- Boehringer Ingelheim$20
- plus $35 from 2 others
What the payments were for
- Food & beverage$294100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $100 |
| Astellas Pharma US Inc | 3 | $57 |
| Daiichi Sankyo Inc. | 1 | $33 |
| Novo Nordisk | 1 | $27 |
| Neos Therapeutics, LP | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Quidel Corporation | 1 | $19 |
| Bioventus LLC | 1 | $16 |
How this compares
$294 in reported general payments places this provider in the 55th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 16 | $14,748 |
| PaxlovidNirmatrelvir/Ritonavir | 19 | $2,859 |
| Rosuvastatin Calcium | 56 | $1,259 |
| SynthroidLevothyroxine Sodium | 19 | $1,051 |
| Atorvastatin Calcium | 71 | $639 |
| ValacyclovirValacyclovir Hcl | 21 | $577 |
| Sertraline Hcl | 21 | $505 |
| Levothyroxine Sodium | 47 | $487 |
| Losartan Potassium | 31 | $431 |
| Amlodipine Besylate | 21 | $425 |
| Fluoxetine Hcl | 12 | $418 |
| Pantoprazole Sodium | 14 | $330 |
| Pravastatin Sodium | 27 | $314 |
| Hydrochlorothiazide | 24 | $283 |
| Olmesartan Medoxomil | 13 | $247 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Silver Spring
- Jose BonelliSilver Spring$40K
- Luis GonzalezSilver Spring$20K
- T Lydel NewsomeSilver Spring$19K
- Marianne MannHighland$2.1M
- Param DedhiaBaltimore$636K
- Curtis RosebraughAshton$418K
- Mark CorriereColumbia$402K
- Gregory PokrywkaTowson$377K
- Shawn DhillonBaltimore$227K
- Brian HarveyAnnapolis$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.